Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA warns against design complacency:

This article was originally published in Clinica

Executive Summary

The FDA has warned US companies not to be complacent about design control requirements despite having a one-year grace before they become fully implemented in June 1998. Speaking at an FDA/Food and Drug Law Institute conference last week, FDA quality system expert, Kim Trautman, told companies they needed to make good use of this grace period to "fine-tune their design control systems". Last week the FDA issued a final guidance document on its design control rules.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT084022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel